Review of maintenance of response to psoriasis treatments

Autor: Dane Hill, Simona Bartos, Steven R. Feldman
Rok vydání: 2016
Předmět:
Zdroj: Journal of Dermatological Treatment. 27:293-297
ISSN: 1471-1753
0954-6634
Popis: Biologics are highly effective treatments for moderate-severe psoriasis with a high percentage of patients achieving 75% improvement in Psoriasis Area Severity Index (PASI75) at 12 weeks. However, psoriasis is a chronic disease, and long-term efficacy is critical.Long-term responses of systemic psoriasis treatments and how this effect is reported.A PubMed literature was performed to identify studies describing long-term response rates to available systemic psoriasis treatments. Within these studies, we examined how maintenance rates were reported. All studies with long-term efficacy data ranging from 24 to 244 weeks were considered.Thirteen studies met the inclusion criteria. When comparing medications at 1 year, response rates among the initial treatment groups were best with secukinumab (65.2%) and worst with apremilast (18.7%). Among only initial responders at 10-16 weeks who received 1 year of continuous treatment, maintenance was best with adalimumab (95.2%) and worst with apremilast (61%).The different methodologies used to report maintenance of response over time make it difficult to compare response rates across drugs studied in different trials.Long-term response rates of systemic treatment of psoriasis are high. Effect may be influenced by many factors and can be analyzed in different ways, making comparisons across different trials difficult.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje